Clinical trials: Aromatase Inhibitor
Breast Cancer, Aromatase Inhibitors
Combined Training on Body Composition of Postmenopausal Women Undergoing Treatment for Breast Cancer
Breast cancer is a multifactorial disease affecting women, and one of the treatments for its healing and survival is hormone therapy.
- Conditions
- Breast Cancer, Aromatase Inhibitors, Postmenopausal
- Trial name
- NCT02804308
- Testing
- Combined Training
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Polymorphism, CYP19
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor.
- Conditions
- Polymorphism, CYP19, Aromatase Inhibitor
- Trial name
- CYP19 (NCT01137136)
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center